314 related articles for article (PubMed ID: 32227409)
1. In vitro and in vivo synergistic efficacy of ceritinib combined with programmed cell death ligand-1 inhibitor in anaplastic lymphoma kinase-rearranged non-small-cell lung cancer.
Du P; Hu T; An Z; Li P; Liu L
Cancer Sci; 2020 Jun; 111(6):1887-1898. PubMed ID: 32227409
[TBL] [Abstract][Full Text] [Related]
2. An increase in BAG-1 by PD-L1 confers resistance to tyrosine kinase inhibitor in non-small cell lung cancer via persistent activation of ERK signalling.
Lin PL; Wu TC; Wu DW; Wang L; Chen CY; Lee H
Eur J Cancer; 2017 Nov; 85():95-105. PubMed ID: 28892778
[TBL] [Abstract][Full Text] [Related]
3. Alterations in PD-L1 Expression Associated with Acquisition of Resistance to ALK Inhibitors in ALK-Rearranged Lung Cancer.
Kim SJ; Kim S; Kim DW; Kim M; Keam B; Kim TM; Lee Y; Koh J; Jeon YK; Heo DS
Cancer Res Treat; 2019 Jul; 51(3):1231-1240. PubMed ID: 30653748
[TBL] [Abstract][Full Text] [Related]
4. Ceritinib plus Nivolumab in Patients with Advanced ALK-Rearranged Non-Small Cell Lung Cancer: Results of an Open-Label, Multicenter, Phase 1B Study.
Felip E; de Braud FG; Maur M; Loong HH; Shaw AT; Vansteenkiste JF; John T; Liu G; Lolkema MP; Selvaggi G; Giannone V; Cazorla P; Baum J; Balbin OA; Wang LV; Lau YY; Scott JW; Tan DS
J Thorac Oncol; 2020 Mar; 15(3):392-403. PubMed ID: 31634667
[TBL] [Abstract][Full Text] [Related]
5. Interpretation of ceritinib clinical trial results and future combination therapy strategies for ALK-rearranged NSCLC.
Blakely CM; Riess JW
Expert Rev Anticancer Ther; 2019 Dec; 19(12):1061-1075. PubMed ID: 31809604
[No Abstract] [Full Text] [Related]
6. Impact of cytotoxic chemotherapy on PD-L1 expression in patients with non-small cell lung cancer negative for EGFR mutation and ALK fusion.
Sakai H; Takeda M; Sakai K; Nakamura Y; Ito A; Hayashi H; Tanaka K; Nishio K; Nakagawa K
Lung Cancer; 2019 Jan; 127():59-65. PubMed ID: 30642552
[TBL] [Abstract][Full Text] [Related]
7. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial.
Shaw AT; Kim TM; Crinò L; Gridelli C; Kiura K; Liu G; Novello S; Bearz A; Gautschi O; Mok T; Nishio M; Scagliotti G; Spigel DR; Deudon S; Zheng C; Pantano S; Urban P; Massacesi C; Viraswami-Appanna K; Felip E
Lancet Oncol; 2017 Jul; 18(7):874-886. PubMed ID: 28602779
[TBL] [Abstract][Full Text] [Related]
8. ZYY-B-2, a novel ALK inhibitor, overcomes resistance to ceritinib by inhibiting P-gp function and induces apoptosis through mitochondrial pathway in ceritinib-resistant H2228 cells.
Gao Y; Liu T; Liu J; Yang Y; Sun K; Li Z; Zhai X; Zuo D
Chem Biol Interact; 2023 Jul; 379():110516. PubMed ID: 37116853
[TBL] [Abstract][Full Text] [Related]
9. Niclosamide, an antihelmintic drug, enhances efficacy of PD-1/PD-L1 immune checkpoint blockade in non-small cell lung cancer.
Luo F; Luo M; Rong QX; Zhang H; Chen Z; Wang F; Zhao HY; Fu LW
J Immunother Cancer; 2019 Sep; 7(1):245. PubMed ID: 31511071
[TBL] [Abstract][Full Text] [Related]
10. Vincristine upregulates PD-L1 and increases the efficacy of PD-L1 blockade therapy in diffuse large B-cell lymphoma.
Wei T; Li M; Zhu Z; Xiong H; Shen H; Zhang H; Du Q; Li Q
J Cancer Res Clin Oncol; 2021 Mar; 147(3):691-701. PubMed ID: 33389078
[TBL] [Abstract][Full Text] [Related]
11. ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non-Small Cell Lung Cancer (NSCLC).
Cho BC; Kim DW; Bearz A; Laurie SA; McKeage M; Borra G; Park K; Kim SW; Ghosn M; Ardizzoni A; Maiello E; Greystoke A; Yu R; Osborne K; Gu W; Scott JW; Passos VQ; Lau YY; Wrona A
J Thorac Oncol; 2017 Sep; 12(9):1357-1367. PubMed ID: 28729021
[TBL] [Abstract][Full Text] [Related]
12. P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.
Katayama R; Sakashita T; Yanagitani N; Ninomiya H; Horiike A; Friboulet L; Gainor JF; Motoi N; Dobashi A; Sakata S; Tambo Y; Kitazono S; Sato S; Koike S; John Iafrate A; Mino-Kenudson M; Ishikawa Y; Shaw AT; Engelman JA; Takeuchi K; Nishio M; Fujita N
EBioMedicine; 2016 Jan; 3():54-66. PubMed ID: 26870817
[TBL] [Abstract][Full Text] [Related]
13. Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial.
Kim DW; Mehra R; Tan DSW; Felip E; Chow LQM; Camidge DR; Vansteenkiste J; Sharma S; De Pas T; Riely GJ; Solomon BJ; Wolf J; Thomas M; Schuler M; Liu G; Santoro A; Sutradhar S; Li S; Szczudlo T; Yovine A; Shaw AT
Lancet Oncol; 2016 Apr; 17(4):452-463. PubMed ID: 26973324
[TBL] [Abstract][Full Text] [Related]
14. A Phase III Study of Durvalumab (MEDI4736) With or Without Tremelimumab for Previously Treated Patients With Advanced NSCLC: Rationale and Protocol Design of the ARCTIC Study.
Planchard D; Yokoi T; McCleod MJ; Fischer JR; Kim YC; Ballas M; Shi K; Soria JC
Clin Lung Cancer; 2016 May; 17(3):232-236.e1. PubMed ID: 27265743
[TBL] [Abstract][Full Text] [Related]
15. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study.
Soria JC; Tan DSW; Chiari R; Wu YL; Paz-Ares L; Wolf J; Geater SL; Orlov S; Cortinovis D; Yu CJ; Hochmair M; Cortot AB; Tsai CM; Moro-Sibilot D; Campelo RG; McCulloch T; Sen P; Dugan M; Pantano S; Branle F; Massacesi C; de Castro G
Lancet; 2017 Mar; 389(10072):917-929. PubMed ID: 28126333
[TBL] [Abstract][Full Text] [Related]
16. Management of ceritinib therapy and adverse events in patients with ALK-rearranged non-small cell lung cancer.
Califano R; Greystoke A; Lal R; Thompson J; Popat S
Lung Cancer; 2017 Sep; 111():51-58. PubMed ID: 28838397
[TBL] [Abstract][Full Text] [Related]
17. ASCEND-8 pharmacokinetic, safety, and efficacy data for ceritinib 450 mg with food in patients with anaplastic lymphoma kinase-positive non-small cell lung Cancer: A clinical perspective.
Otoukesh S; Sanchez T; Mirshahidi S; Wallace D; Mirshahidi H
Cancer Treat Res Commun; 2019; 20():100149. PubMed ID: 31075537
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy.
Knudson KM; Hicks KC; Alter S; Schlom J; Gameiro SR
J Immunother Cancer; 2019 Mar; 7(1):82. PubMed ID: 30898149
[TBL] [Abstract][Full Text] [Related]
19. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
Xia L; Liu Y; Wang Y
Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity and combined inhibitory effect of ceritinib with gemcitabine in pancreatic cancer.
Jamshed MB; Munir F; Shahid N; Sadiq U; Muhammad SA; Ghanem NB; Zhong H; Li X; Zhang Q
Am J Physiol Gastrointest Liver Physiol; 2020 Jan; 318(1):G109-G119. PubMed ID: 31736340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]